Stifel analyst Jonathan Block upgraded Inspire Medical (INSP) to Buy from Hold with a price target of $110, up from $100. The company’s headwinds are easing following Friday night’s large positive reimbursement revision, the analyst tells investors in a research note. Stifel sees Inspire’s headwinds turning into tailwinds, including patient warehousing, which it believes will now likely aid 2026 volumes. In addition, Inspire’s advertising spend, which was curtailed notably in 2024 and early-2025, has picked up lately, the firm adds.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSP:
- Positive Outlook for Inspire Medical Systems: Increased Reimbursement Rates and Strategic Advantages Drive Buy Rating
- Inspire Medical sees $90M-$100M income tax benefit for FY25
- Inspire Medical Systems to Release Tax Valuation Allowance
- Inspire Medical Faces Legal Heat Over Product Launch
- Inspire Medical participates in a conferene call with JPMorgan